Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 133-139

  Minkin, Mary Jane ^a   Maamari, Ricardo ^b   Reiter, Suzanne ^c  

^a Temple Medical Center   (United States)

^b NOVO NORDISK INC   (United States)

^c Mid County Health Center   (United States)

Author keywords

Conjugated estrogen vaginal cream; Estradiol; Local estrogen therapy; Vaginal atrophy; Vaginal cream; Vaginal ring; Vaginal tablet

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; UNCLASSIFIED DRUG; VAGIFEN;

ADULT; ARTICLE; CREAM; DRUG EFFICACY; DRUG PREFERENCE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT SATISFACTION; POSTMENOPAUSE; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA ATROPHY; VAGINA RING;

EID: 84875134376     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S41897     Document Type: Article

References (17)

1. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94.
2. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096.
3. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355-369.
4. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med. 2009;6(1):30-39.
5. Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause. 2009;16(3): 442-452.
6. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15(4 Pt 1):661-666.
7. Wyeth. REVEAL Revealing Vaginal Effects At Mid-Life: Surveys of postmenopausal women and health care professionals who treat post- menopausal women. Available from: http://www.revealsurvey.com/pdf/ reveal-survey-results.pdf. Accessed April 6, 2012.
8. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233-238.
9. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357-369.
10. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522.
11. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health. 2010;1:105-111.
12. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500.
13. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-2142.
14. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA) - results from an international survey. Climacteric. 2012; 15(1):36-44.
15. Shulman L P, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt). 2008; 17(4):569-578.
16. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44.
17. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta- estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000; 7(3):156-161.